Overview

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

Status:
Recruiting
Trial end date:
2022-12-17
Target enrollment:
0
Participant gender:
All
Summary
This research study will evaluate the effectiveness and estimate the feasibility of administering an investigational drug called 'CN-105' (the study drug), to prevent postoperative cognitive decline, delirium (serious confusion) and underlying brain inflammatory and brain activity changes in adults 60 years and older undergoing surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Miles Berger, MD PhD
Criteria
Inclusion Criteria:

- Age ≥ 60

- Ability to speak English

- Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last
> 2 hours; due to be admitted to the hospital following surgery

Exclusion Criteria:

- Inmate of a correctional facility

- Scheduled to receive systemic chemotherapy between the time of the two cognitive
testing sessions

- Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other
clinical contraindication known ahead of time.

- Inappropriate for study inclusion based on the judgement of the principal
investigator.

- If a patient undergoes major head trauma that occurs between the times of the two
cognitive testing sessions, then they will be withdrawn from the study.